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Role of mitral valve repair in active
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Abstract
Background: Although mitral valve repair is at present the technique of choice in mitral regurgitation (MR) due to
degenerative valve disease, long term results in patients with active mitral infective endocarditis (IE) are still under
evaluation.
Methods: In the study were included 34 consecutive patients (22 males; mean age, 60 years; range 32–84
years) referred to our institution between January 1, 2005 to December 31, 2011 who were treated with valve
repair for mitral valve (MV) active infective endocarditis. Eighteen patients underwent isolated MV repair.
Aortic valve replacement and respectively repair were performed in 9 and 2 patients with concomitant aortic
involvement. Blood cultures were positive in 30 (17 Staphylococcus, 13 Streptococcus, 1 g negative, 2
enterococcus).
Results: Four patients died during hospital stay (11%) due to multi system organ failure as a consequence of
severe septic shock (2 patients), cardiogenic shock (1 case) and respiratory failure (1 patient). At an average
follow up of 48 months in patients discharged alive from hospital survival was 96.7% (29 out of 30). None
developed more than mild- to moderate mitral valve regurgitation during follow-up and we found a
significant improvement in functional capacity and left ventricular ejection fraction associated with a
significant decrease of pulmonary artery pressure. The only recurrence of endocarditis occurred in a drug
addict patient.
Conclusions: Present investigation suggest that in patients with active mitral valve endocarditis MV repair,
when technically feasible, is associated with a favorable clinical long term outcome. None of the patients
alive at the end of follow-up developed severe mitral regurgitation. Moreover mortality and reinfection rate
are uncommon and functional improvement.
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Background
Surgical treatment in mitral valve infective endocar-
ditis (IE) is indicated in patients with severe mitral
regurgitation, even in absence of congestive heart fail-
ure, with mitral annular abscess, large vegetation
(>10 mm), uncontrolled sepsis and multiple emboli
[1]. Mitral valve (MV) replacement has traditionally
been considered the standard treatment for MV endo-
carditis unresponsive to antibiotic therapy, because of
concerns about the durability of mitral valve repair,
recurrence of IE, and mitral regurgitation [2–4]. Since
the pioneer work by Dreyfus et al. [5] several authors
suggested that in patients undergoing surgery for IE
mitral valve repair may be safely performed and is
often associated with a better outcome compared with
mitral valve replacement [6–10]. A systematic review
by Ferringa et al. [11] underlined that mitral valve
repair was possible in approximately 39% of patients
presenting with mitral valve endocarditis. Valve repair
was associated with lower in-hospital and long term
mortality [4, 6, 8]. Aim of present investigation was
to evaluate at an average 4 years follow-up period the
clinical and functional results of mitral valve repair in
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a group of consecutive patients with active mitral IE
referred to our institution.
Methods
In the study were included 34 consecutive patients
referred to Heart Surgery Department of Azienda
Ospedaliera Universitaria Careggi, Florence, Italy, a
tertiary heart surgery referral center serving a population >
1.5 million, between January 1, 2005 and December 31,
2011 and treated with mitral valve repair for active infect-
ive endocarditis defined in agreement with the criteria of
European Society of Cardiology [12]. Diagnosis of IE was
made according to modified Duke University criteria [13]
From the study were excluded patients undergoing mitral
valve repair in healed endocarditis. Overall 34 patients, 22
males and 12 females, mean age 58 years (range 32–84
years) were enrolled in the investigation. The preoperative
patient characteristics are reported in Table 1.
At hospital admission 65% of patients was in New
York Heart Association (NYHA) functional class III-IV,
26 and 9% respectively in class II and class I. Five
patients had history of recent dental procedures, two
patients were intravenous drug addicts. Causative micro-
organisms were isolated and identified in blood cultures
in 30/34 patients. The aetiologic agents were Streptococ-
cus species in 17 patients (50%) and Staphylococcus
species in 10 (29,4%) patients. Antibiotic treatment was
targeted according to results of antibiotic susceptibility
testing. As suggested by the guidelines, large spectrum
empiric antibiotic treatment was prescribed in patients
with culture negative endocarditis [10, 11]. Indications
to surgery has been: congestive heart failure with
hemodynamic impairment in 4 patients, vegetation >
10 mm in diameter in 16, recurrent embolic event in 4
and persistent fever or perivalvular spreading of infec-
tion after at least 1 week of targeted antibiotic therapy in
10. All patients underwent surgery within 7 days after
starting antibiotic treatment, unless impairment of
clinical conditions suggested an earlier solution.
Informed consent was obtained from each patient and
the study protocol conforms to the ethical guidelines of
the 1975 Declaration of Helsinki as reflected in a priori
approval by the institution’s human research committee.
Transthoracic and transesophageal (TEE) echocardiog-
raphy were performed with a Sequoia Accuson instrument
(Siemens Medical Solution, Mount View, California, USA).
All examinations were performed by two senior echocar-
diographers adhering to American Society of Echocardio-
graphy guidelines [11]. Standard semi-quantitative method
was used to assess the severity of regurgitation: absent, mild
(<2+) or moderate-severe (3 + − 4+). Left ventricular ejec-
tion fraction (LVEF) was measured using area-lenght
method. The examination was performed before and 2–3
days after surgery. Repair or replacement strategy were
planned before surgery on the basis of anatomical charac-
teristics and degree of tissue valve destruction and paraval-
vular extension of infection evaluated by trans esophageal
echocardiography. After direct inspection in operating
room only one patient scheduled for repair was shifted to
valve replacement.
Surgical treatment:All procedures were performed
through a median sternotomy and involved cardiopulmo-
nary bypass with bicaval cannulation, Myocardial protec-
tion was identical for all patients and consisted of
antegrade cold blood cardioplegia. The MV was exposed
through a right-sided left atriotomy. The whole procedure
was conducted under continuous TEE monitoring. The
basic surgical principle was radical resection of all infected
valvular and subvalvular tissue. 18 patients were treated
with isolated MV repair. Associated procedure were
performed in the remaining 16 patients including aortic
valve replacement and repair, tricuspid valve annuloplasty,
coronary artery bypass and a radiofrequency ablation
procedure (Table 2). Triangular or quadrangular resection
with sliding were used in 22 patients for anterior and
posterior leaflet reconstruction. Glutaraldehyde-treated
autologous pericardial patches were used in 6 patients and
artificial chordal replacement was performed in 2 cases.
Table 1 Preoperative profile of the 34 patients with active
infective endocarditis
Variable
Age (years) 58 ± 17
Male/Female 22/12
LVEF % 57 ± 3
Systolic blood pressure mmHg 127 ± 13
Diastolic blood pressure mmHg 74 ± 7
Heart rate beats/min 81 ± 20
NYHA class Patient number
I 3
II 9
III 17
IV 5
Aetiologic agent
Staphylococcus 10
Streptococcus 17
Gram - 1
Enterococcus 2
Negative blood colture 4
Indication to surgery
Peri valvular spreading of infection 10
Congestive heart failure 4
> 10 mm vegetations 16
Recurrent embolic event 4
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The ring used for annuloplasty was autologous pericar-
dium in 1 patient and prosthetic in 28 cases.
After discharge, all patients were admitted to a rehabili-
tation centre and thereafter followed by their general prac-
titioner. Antibiotic treatment (according to antimicrobial
susceptibility testing in patients with positive blood
cultures and empirical in patients with negative blood
cultures) was prosecuted for at least 6 weeks after surgery.
Clinical examination were scheduled (3, 12, 24, 32 and
48 months). The mean follow-up period after discharge
has been 4 years.
Statistical analysis
The quantitative variables are reported as means and
standard deviations. In case of not continuous parame-
ters the frequency of distribution has been reported. The
statistical analysis of clinical data was carried out by the
Student’s t test for continuous data, while for not
continuous variables χ2 test was used. The analysis of
survival was made using the Kaplan- Meier method. A
probability value of < 0.05 was considered statistically
significant.
Results
Four of 34 patients included in the study died during
hospital stay (11%). All deaths were due to multisystem
organ failure as consequence of severe septic shock (2
patients), cardiogenic shock (1 case) and respiratory
failure (1 patient). In 2 patients, the microorganisms re-
sponsible for endocarditis was a methicillin-resistant
staphylococcus aureus, in one case a Streptoccoccus
parasanguinis and in the last patient blood culture was
negative.
In patients discharged alive from hospital survival was
96.7% (29 out of 30) at an average follow up of 48 months
(Fig. 1). One patient underwent double valve surgery (mi-
tral valve repair and Bentall’s intervention) died 3 months
postoperatively of sudden death. Endocarditis recurred
only in 1 patient (intravenous drug user) 11 months
postoperatively; he needed reintervention.
Surgical treatment led to a significant functional
improvement. At the end of the follow-up 90% (27 out
of 30) of the patients discharged alive from hospital were
in NYHA class I, II and all the patients were in sinus
rhythm. Transthoracic echocardiography showed a
significant decrease of left ventricular end diastolic
diameter, an improvement of left ventricular ejection
fraction and decrease of pulmonary artery pressure. At
last examination none developed severe mitral regurgita-
tion, 20 patients had mild (≤2+) and 9 had no or trivial
mitral valve regurgitation. Pulmonary systolic pressures
were significantly diminished at the time of follow-up.
Pre- and postoperative echocardiographic data are sum-
marized in Table 3.
Discussion
In agreement with more recent data suggesting a decreased
risk of mortality, stroke, recurrent endocarditis and re-
operation after valve repair [6–11], in our institution
we had a progressive trend towards conservative
treatment also in patients with active endocarditis. At
present less than 40% of mitral valve endocarditis
undergo mitral valve replacement.
Resection technique should allow excision of enough
leaflet tissue to ensure eradication of the infectious
process. Anterior leaflet lesions, commissural lesions,
extensive leaflet destruction and paravalvular abscess
may require different and often complex techniques for
MV repair [14]. Annuloplasty using a prosthetic ring
provides coaptation of leaflets, limits tension in the
suture, prevents further dilation of the annulus allowing
a stable late surgical result [2, 6, 8]. Autologous pericar-
dium is an alternative material for annuloplasty in
patients with active IE. We used autologous pericardium
for annuloplasty in one patient. MV repair, maintaining
the annular-chordal-papillary muscle continuity, may
allow to obtain more frequently the recovery of left
ventricle geometry in comparison to mitral valve
replacement, moreover it decreases the risk related to
prolonged anticoagulation [15]. Several studies have
shown that valve repair in IE is associated with lower in-
hospital and long term mortality. Moreover a decreased
risk of stroke, recurrent endocarditis and reoperation
has been reported [8, 11].
Table 2 Operative procedures
Procedures n patient
Patch repair of AML 7
Patch repair of PML 1
Articial chordae 2
Annuloplasty:
Prosthetic ring 28
Autologous pericardium 1
Quadrangular resection PML 16
Triangular resection PML 5
Triangular resection AML 1
Edge to edge 1
Associated operation
Aortic valve replacement 9
Aortic valve repair 2
Coronary artery by pass 3
Maze operation 1
Tricuspid valve repair 1
AML anterior mitral leaflet, PML posterior mitral leafet
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Omoto et al. [16] performed valve repair in 68% (15/
22) of patients with mitral valve endocarditis. Seven out
of 15 cases required a complex repair. 3/15 (20%)
patients required reintervention due to dehiscence of the
pericardial patch. Ruttman et al. [17] studied 68 con-
secutive patients needing surgery for mitral endocarditis.
Thirty-four (50%) patients had valve repair, and 34 (50%)
patients had valve replacement. Hospital mortality was
11.8% (8 patients). No significant differences were found
in all baseline parameters, with the exception of a higher
incidence of previous septic embolism and sepsis in the
repair group. At 1 year actuarial event-free survival was
88.2% in the repair group compared with 67.7% in
the replacement group. In the study by Kanemitsu et
al. [18] 43 patients who underwent primary MV re-
pair for IE at a single center between 1991 and 2009
were retrospectively examined. Survival was 92.6 ±
4.1% at 5 years. The rates of freedom from MV reop-
eration was 90.5 ± 4.5% and for freedom from moder-
ate or severe MR was 95.0 ± 3.5%. Recurrence of
endocarditis was observed in 2 patients (4.7%). Most
(86%) of the survivors were in NYHA class I.
MV repair was possible in 60% of patients with ac-
tive mitral IE referred to our institution. Despite
antibiotic treatment and early surgical treatment post-
operative mortality in patients with active-phase in-
fective endocarditis remain high. In present study in
hospital mortality was 11%, similar to that reported in
previous studies (8–12%). Long term survival of
discharged patients, 96.7%, is similar to that reported
by Kanemitsu [18] and higher than in other studies
[11, 17]. All patients showed a significant improve-
ment in functional capacity. 93.2% were in NYHA
functional class I-II at follow-up. In our investigation
none patients developed more than mild to moderate
mitral regurgitation, while at least a 5% of severe re-
gurgitation was found at follow-up in other studies
[11, 16, 19]. As shown by Ruttmann et al. [17] mitral
valve repair is associated with a lower rate of reinfec-
tion in comparison to mitral valve replacement; 4% vs
17%. A high risk condition (drug addiction) was
present in the only patient with recurrent IE observed
in our study. The use of prosthetic material in MV
repair in active IE is still controversial since the use
of a prosthetic annuloplasty ring may be associated
with a higher risk of endocarditis recurrence. A
prosthetic ring was used in 28/29 patients and we did
not find any device related infection.
Streptococci were the more frequent etiologic agents
(50%) in our study, in agreement with previous investi-
gations [16, 18]. It is conceivable that a more limited
Fig. 1 Left survival curve the first 100 days after surgery. Left – long term survival curve in patients discharged alive from the hospital
Table 3 Preoperative and follow-up echocardiographic and
functional parameters
Parameter Preoperative Follow up
LV Ejection fraction (%)
> 50% 26 29
35–50% 4 0 χ2 5.472
< 35% 4 0 p 0.065
Pulmonary systolic pressure (mmHg)
> 50 mmHg 6 0
30–50 mmHg 19 14 χ2 7.264
< 30 mmHg 9 15 p 0.0265
LV end diastolic diameter (mm)
< 55 mm 17 24
55–60 mm 3 5 χ2 16.92
> 60 mm 14 0 p 0.0002
Mitral regurgitation
0 0 9
< 2+ 4 20 χ2 47.57
3+ 4+ 30 0 p < 0.0001
NYHA functional class
I 3 17
II 9 10 χ2 25.69
III 17 2 p < 0.0001
IV 5 0
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damage to valve structure related to the lower virulence
of streptococcal infection allowed more frequently to
perform MV repair.
Limitation to the study
The absence of a control group of patients undergoing
mitral valve replacement for active infective endocarditis
does not allow a direct comparison of the two surgical
techniques. It is likely that the study may suffer the bias
that patients with fewer comorbidities and less aggres-
sive infection were selected for repair. The superiority
demonstrated by mitral valve repair over valve replace-
ment in the only study that directly compared these 2
surgical techniques [17] makes ethically difficult to
suggest a randomized study. Although characteristics of
the groups in the randomized study did not significantly
differ as the authors state “it is very difficult to be sure
that the characteristics of the patients and, especially, of
the valves are identical. Also, we cannot neglect effects
caused by the surgeon’s experience.”
Conclusion
MV repair is an attractive surgical option in patients
with active IE. Expertise of surgical team and favorable
anatomical conditions allowed to preserve mitral valve
in 60% of patients referred to our institution. Results
from present study suggest that mitral valve repair in
active-phase infective endocarditis is associated with a
good long-term outcome (high long-term survival, sig-
nificantly recovery of functional capacity, low reinfection
rate). Moreover at the end of follow-up no patients
showed severe valve regurgitation. In conclusion, in our
opinion, when technically feasible mitral valve repair
should be preferred to mitral valve replacement in
patients with active mitral IE.
Abbreviations
IE: Infective endocarditis; LVEF: Left ventricular ejection fraction; MR: Mitral
regurgutation; MV: Mitral valve; NYHA: New York Heart Association;
TEE: Transesophageal echocardiograèhy
Acknowledgements
None.
Funding
Individual funds for research from Florence University (CR).
Availability of data and materials
Data set may available under request.
Authors’ contributions
CR and PLS ideated the study and contributed in writing the manuscript CR
and EC analyzed and interpreted the data. All authors read and approved
the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
None material need consent.
Ethics approval and consent to participate
Informed consent was obtained by patinent. The study was approved by
Ethical Committee of AOU Careggi -Firenze.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Dipartimento Medicina sperimentale e clinica, Università di Firenze, Viale
Morgagni 85, 50134 Florence, Italy. 2Medicina Interna e Postchirurgica, AOU
Careggi Firenze, Florence, Italy. 3Cardiochirurgia, AOU Careggi Firenze,
Florence, Italy.
Received: 16 November 2016 Accepted: 10 May 2017
References
1. Bonow RO, Carabello BA, Chatterjee K, de Leon A, Faxon DP, Freed MD, et
al. 2008 Focused update incorporated into the ACC/AHA 2006 guidelines
for the management of patients with valvular heart disease: A report of the
American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (writing committee to revise the 1998 guidelines for the
managemen of patients with valvular heart disease). Circulation. 2008;118:
e523–661. doi:10.1161/CIRCULATIONAHA.108.190748.
2. Iung B, Rousseau-Paziaud J, Cormier B, Garbarz E, Fondard O, Brochet E,
Acar C, Couëtil JP, Hvass U, Vahanian A. Contemporary results of mitral
valve repair for infective endocarditis. J Am Coll Cardiol. 2004;43(3):386–92.
3. Podesser BK, Rödler S, Hahn R, Eigenbauer E, Vodrazka M, Moritz A, et al.
Mid-term follow up of mitral valve reconstruction due to active infective
endocarditis. J Heart Valve Dis. 2000;9:335–40.
4. Senni M, Merlo M, Sangiorgi G, Gamba A, Procopio A, Glauber M, et al.
Mitral valve repair and transesophageal echocardiographic findings in a
high-risk subgroup of patients with active, acute infective endocarditis. J
Heart Valve Dis. 2001;10:72–7.
5. DreyfusG SA, JebaraVA DA, ChauvaudS CJP, Carpentier A. Valve repair in
acute endocarditis. Ann Thorac Surg. 1990;49(5):706–11. discussion 712–3.
6. Sternik L, Zehr KJ, Orszulak TA, Mullany CJ, Daly RC, Schaff HV. The advantage
of repair of mitral valve in acute endocarditis. J Heart Valve Dis. 2002;11:91–8.
7. Muehrcke DD, Cosgrove 3rd DM, Lytle BW, Taylor PC, Burgar AM, Durnwald CP,
Loop FD. Is there an advantage to repairing infected mitral valves? Ann Thorac
Surg. 1997;63:1718–24S.
8. Sheikh AM, Elhenawy AM, Maganti M, Armstrong S, David TE, Feindel CM.
Outcomes of surgical intervention for isolated active mitral valve endocarditis.
J Thorac Cardiovasc Surg. 2009;137(1):110–6. doi:10.1016/j.jtcvs.2008.07.033.
9. Zegdi R, Debièche M, Latrémouille C, Lebied D, Chardigny C, Grinda JM, et
al. Long-term results of mitral valve repair in active endocarditis. Circulation.
2005;111:2532–6.
10. de Kerchove L, Price J, Tamer S, Gilneuer D, Momeni M, Norihomme P, et al.
Extending scope of mitral valve repair in active endocarditis. J Thorac
Cardiovasc Surg. 2012;143:s91–5.
11. Ferringa HH, Shaw LJ, Poldermans D, Hoeks S, van der Wall EE, Dion RA, et
al. Mitral valve repair and replacement in endocarditis: a systemic review of
literature. Ann Thorac Surg. 2007;83:564–71.
12. Cheitlin MD, Alpert JS, Armstrong WF, et al. ACC/AHA guidelines for the
clinical application of echocardiography: executive summary: a report of the
American College of Cardiology/American Heart Association Task Force on
Practice Guidelines (Committee on Clinical Application of
Echocardiography): developed in collaboration with the American Society
of Echocardiography. J Am Coll Cardiol. 1997;29:862–87.
13. Li JS, Sexton DJ, Mick N, Nettles R, Fowler Jr VG, Ryan T, Corey GR, Bashore T.
Proposed modifications to the Duke criteria for the diagnosis of infective
endocarditis. Clin Infect Dis. 2000;30(4):633–8. Epub 2000 Apr 3.
14. Miura T, Hamawaki M, Hazama S, Hashizume K, Ariyoshi T, Sumi M, et al.
Outcome of surgical management for active mitral native valve endocarditis: a
collective review of 57 patients. Gen Thorac Cardiovasc Surg. 2014;62:488–98.
15. Bishara J, Leibovici L, Gartman-Israel D, Sagie A, Kazakov A, Miroshnik E,
Ashkenazi S, Pitlik S. Long-term outcome of infective endocarditis: the
impact of early surgical intervention. Clin Infect Dis.
2001;33(10):1636–43. Epub 2001.
Rostagno et al. Journal of Cardiothoracic Surgery  (2017) 12:29 Page 5 of 6
16. Omoto T, Tedoriya T, Oi M, Nagai N, Miyauchi T, Ishikawa N. Significance of
mitral valve repair for active-phase infective endocarditis. Asian Cardiovasc
Thorac Ann. 2011;19(2):149–53.
17. Ruttmann E, Legit C, Poelzl G, Mueller S, Chevtchik O, Cottogni M, Ulmer H,
Pachinger O, Laufer G, Mueller LC. Mitral valve repair provides improved
outcome over replacement in active infective endocarditis. J Thorac
Cardiovasc Surg. 2005;130(3):765–7.
18. Kanemitsu H, Nakamura K, Fukunaga N, Koyama T. Long-term outcomes of
mitral valve repair for active endocarditis. Circ J. 2016;80:1148–52.
19. David TE, Gavra G, Feindel CM, Regesta T, Armstrong S, Maganti MD.
Surgical treatment of active infective endocarditis: a continued challenge.
J Thorac Cardiovasc Surg. 2007;133(1):144–9. Epub 2006 Nov 30.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Rostagno et al. Journal of Cardiothoracic Surgery  (2017) 12:29 Page 6 of 6
